Abstract
Aim:
To compare clinical, cost-effect efficacies and safety of simvastatin Zokor and generic Vasilip in correction of dislipoproteinemia in patients with ischemic heart disease.
Material and methods:
The original statin Zokor and generic statin Vasilip were given for 8 weeks in a dose 20 mg/day.
Results:
Vasilip and Zokor demonstrated similar hypolipidemic efficacy and safety, but Vasilip administration was more cost-effective.
Conclusion:
Simvastatin Vasilip is recommended for wider use in clinical practice because it is clinically and cost effective.
Publication types
-
Clinical Trial
-
Comparative Study
-
English Abstract
MeSH terms
-
Cholesterol / blood
-
Drug Costs*
-
Drugs, Generic* / adverse effects
-
Drugs, Generic* / economics
-
Drugs, Generic* / therapeutic use
-
Female
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / economics
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
-
Hyperlipidemias / blood
-
Hyperlipidemias / diet therapy
-
Hyperlipidemias / drug therapy*
-
Lipoproteins, HDL / blood
-
Lipoproteins, LDL / blood
-
Male
-
Middle Aged
-
Simvastatin* / adverse effects
-
Simvastatin* / economics
-
Simvastatin* / therapeutic use
-
Triglycerides / blood
Substances
-
Drugs, Generic
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Lipoproteins, HDL
-
Lipoproteins, LDL
-
Triglycerides
-
Cholesterol
-
Simvastatin